Why the study?
Elevated triglycerides and insulin resistance are common in metabolic disorders, and saroglitazar provides dual PPAR alpha and gamma agonism that may reduce high triglycerides, improve insulin sensitivity, and lower liver fibrosis.
Does saroglitazar combined with atorvastatin reduce hypertriglyceridemia and liver fibrosis in a patient with diabetic dyslipidemia?
Does saroglitazar combined with atorvastatin reduce hypertriglyceridemia and liver fibrosis in a patient with diabetic dyslipidemia?
Saroglitazar combined with atorvastatin dramatically reduced severe hypertriglyceridemia and liver stiffness in a young patient with diabetic dyslipidemia.
Metabolic disorders are characterized by pathologies like visceral adiposity, hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, impaired glucose tolerance, fatty liver, and so on, with insulin resistance being the main contributing factor. Insulin resistance and diabetes mellitus are commonly associated with elevated triglyceride levels. Among the available medications for treating metabolic disorders, only Saroglitazar has a dual peroxisome proliferator-activated receptor ɑ + γ action that can reduce high triglycerides and improve insulin sensitivity. This medication may also reduce liver fibrosis content. The present case report illustrates the efficacy of Saroglitazar in reducing hypertriglyceridemia and liver stiffness as assessed by shear wave elastography.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: